All Drug Targets articles – Page 20
-
NewsEnhanced NPC cultivation furthers understanding of kidney disease
Induced NPCs facilitate the creation of patient-specific organoid models and improve identification of nephron targeted drugs.
-
NewsNew methodologies to find microbiome biomarkers
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
-
NewsDiscovery of over 100 genomic loci linked to hypertension
The study’s findings explain the genetic differences in people’s blood pressure, which could lead to personalised medicine approaches.
-
NewsXCL1 could mitigate psychiatric condition risk in offspring
Adult anxious behaviour in offspring may be related to the early life proinflammatory state caused by the absence of elevated XCL1.
-
NewsMini-colons reveal complex process of tumorigenesis ex vivo
The mini-colons are topobiologically complex, can be induced to develop tumours in targeted areas and reduce the use of animal models.
-
NewsNew single-cell lipidomics method may unlock cancer treatments
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
-
NewsExploring the role of class IIa HDACs in inflammatory diseases
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
-
NewsTargeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
-
News
Mitochondrial depletion results in abnormal protein accumulation
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
-
NewsEvaluating the anti-obesity effects of tocotrienols
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
-
NewsElucidating the mechanism that initiates cancer cachexia
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
-
NewsMelanoma tumours produce altBRAFs by genomic deletions
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
-
NewsElevated TMAO levels predict future risk of CKD
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
-
ArticleIdentifying vascular disease associations
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
-
NewsLink identified between bacteria and cancer treatment efficacy
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
-
NewsExploring the effects of IFNβ in neuroHIV infection
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
-
NewsRare genetic variants found to have a large impact on obesity risk
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
-
NewsExploring the conditions in which pathological 4R tau misfolds
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
-
NewsNew treatment for metabolic dysfunction-associated steatohepatitis
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
-
ArticleInvestigating antipsychotics in a Parkinson’s disease psychosis model
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.